Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.
Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.
… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.
… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures.
… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.
Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.
… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.
… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures.
… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.
Location: Belgium, Brussels-Capital, City of Brussels
Employees: 11-50
Founded date: 2015
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B
Portfolio 9
| Date | Name | Website | Total Raised | Location |
| 26.07.2024 | Catalym | catalym.com | $261.12M | Germany, B... |
| 13.05.2024 | SynOx Ther... | synoxtherapeutics.com | $231.8M | Ireland, D... |
| 13.05.2024 | Commit Bio... | commitbio.com | $35.01M | - |
| 02.05.2023 | Anavo Ther... | anavotx.com | $85.32M | Netherland... |
| 06.03.2023 | Bicara The... | bicara.com | $635M | United Sta... |
| 15.10.2022 | Tridek One | tridekone.com | $17.42M | France, Il... |
| - | Primmune T... | primmunerx.com | $15.4M | United Sta... |
| - | Enhanc3D G... | enhanc3dgenomics.com | $12.72M | United Kin... |
| - | Egle Thera... | egle-tx.com | - | France, Il... |
Persons 17
| Date | First Name | Last Name | Title | Location | |||
| - | Debora | Dumont | Managing P... | linkedin.c... | - | - | - |
| - | Olivier | Houben | - | linkedin.c... | - | - | - |
| - | Tom | Heyman | - | - | - | - | |
| - | Alexander | Demoulin | Associate | linkedin.c... | - | - | - |
| - | Joris | Vanderloch... | Chief Scie... | linkedin.c... | - | - | - |
| - | Tol | Trimborn | - | linkedin.c... | - | - | - |
| - | Jacques | Mizrahi | - | linkedin.c... | - | - | - |
| - | Joris | De Maeyer | Executive ... | linkedin.c... | - | - | - |
| - | Clement | Salque | Junior Ass... | linkedin.c... | - | - | - |
| - | Jon | Edwards | Investment... | linkedin.c... | - | j*n@redtre... | - |
Show more
News 40
| Date | Title | Description |
| 17.10.2024 | Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US | Leiden, The Netherlands – October 9, 2024 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, today announced the appointment of Edward Holson, Ph.D., as Chief Scientific Officer (CSO). ... |
| 21.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the cl... |
| 07.09.2024 | Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease | Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdi... |
| 07.09.2024 | Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development | BOSTON, Mass., March 26, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as ... |
| 07.09.2024 | Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever | – PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate... |
| 07.09.2024 | SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT | Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led... |
| 07.09.2024 | Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 mont... |
| 07.09.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunit... |
| 07.09.2024 | EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Indepen... | Paris, France, May [date], 2024 – EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appoin... |
| 07.09.2024 | Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. | BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christ... |
Show more
Mentions in press and media 3
| Date | Title | Description |
| 03.05.2023 | Dutch-based Anavo Therapeutics secures €8.5M to systematically drug phosphatases: Know more | Leiden-based Anavo Therapeutics, a company that claims to be the first to systematically drug phosphatases – a rich target space previously considered undruggable for decades, announced that it has raised €8.5M in a Seed extension round of ... |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers About Egle Therapeutics About LSP About Bpifrance – InnoBio 2 About Tak... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |